2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.26 Cooper

PP01.26 Cooper - Poster

Pdf Summary

The study examines the pre-treatment neutrophil-lymphocyte ratio (NLR) as a prognostic biomarker in non-small cell lung cancer patients treated with third-generation EGFR Tyrosine Kinase Inhibitors (TKIs). The research involved analyzing data from 606 NSCLC patients, with a focus on 151 patients treated with EGFR TKIs divided by generation. Results indicate that NLR may be significantly associated with survival outcomes in patients receiving 1st or 2nd generation TKIs but not in those receiving 3rd generation TKIs. Variables impacting patient survival in the 1st/2nd generation group included smoking status, BMI, and brain metastases, while no significant impact was observed in the 3rd generation group. The study suggests that NLR's prognostic utility is limited to patients treated with older generation TKIs. Furthermore, differences in NLR's predictive efficacy between the generations indicate that 3rd generation TKIs can potentially benefit patients regardless of performance status. The research underscores the importance of considering baseline laboratory data to predict outcomes, particularly for patients on older generation EGFR TKIs. These findings contribute to understanding the efficacy of NLR as a prognostic biomarker in NSCLC patients undergoing EGFR TKI treatment, highlighting potential differences based on the generation of the TKIs used.

Keywords

Neutrophil-lymphocyte ratio

NLR

Prognostic biomarker

Non-small cell lung cancer

EGFR Tyrosine Kinase Inhibitors

TKIs

Survival outcomes

1st generation TKIs

2nd generation TKIs

3rd generation TKIs